Form 4: Vertex Pharmaceuticals Director Nancy Thornberry Reports Acquisition of Common Stock and Stock Options

Director Nancy Thornberry reports acquisition of Vertex Pharmaceuticals common stock and stock options.

Summary

• On May 1, 2025, Nancy Thornberry, a director of Vertex Pharmaceuticals, reported acquiring 398 shares of common stock and 1,199 stock options.
• The common stock was acquired at a price of $0, and the director now beneficially owns 2,035 shares.
• The stock options have an exercise price of $502.97, are fully vested, and expire on April 30, 2035.
• The director directly owns 1,199 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Vertex Pharmaceuticals, Director, Stock Options, Common Stock, Acquisition, Beneficial Ownership, Form 4, VRTX